Project Details
Project Description
This project will operationalise the first 2 years of CCRM Australia's 5 Year Strategic Plan that aims to accelerate the commercialization of Australian regenerative medicine technologies, therapies and related products.
This project builds CCRM Australia's capability and fosters increased collaboration between industry, clinicians and academia, both locally and globally; and nurturing local regenerative medicine companies for the international market.
This project builds CCRM Australia's capability and fosters increased collaboration between industry, clinicians and academia, both locally and globally; and nurturing local regenerative medicine companies for the international market.
| Short title | Operationalising CCRM AU |
|---|---|
| Status | Finished |
| Effective start/end date | 1/01/18 → 30/09/19 |
Funding
- Monash University – Internal Faculty Contribution: A$100,000.00
Research output
- 1 Article
-
Safety, tolerability and efficacy of intra-articular Progenza in knee osteoarthritis: A randomized double-blind placebo-controlled single ascending dose study
Kuah, D., Sivell, S., Longworth, T., James, K., Guermazi, A., Cicuttini, F., Wang, Y., Craig, S., Comin, G., Robinson, D. & Wilson, J., 6 Mar 2018, In: Journal of Translational Medicine. 16, 49.Research output: Contribution to journal › Article › Research › peer-review
Open AccessFile103 Link opens in a new tab Citations (Scopus)